UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 10 von 292
Datensatz exportieren als...
BibTeX
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data
International journal of geriatric psychiatry, 2001-12, Vol.16 (S1), p.S33-S61
Kennedy, John S.
Bymaster, Frank P.
Schuh, Leslie
Calligaro, David O.
Nomikos, George
Felder, Christian C.
Bernauer, Mark
Kinon, Bruce J.
Baker, Robert W.
Hay, Donald
Roth, H. John
Dossenbach, Martin
Kaiser, Christopher
Beasley, Charles M.
Holcombe, John H.
Effron, Mark B.
Breier, Alan
2001
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Kennedy, John S.
Bymaster, Frank P.
Schuh, Leslie
Calligaro, David O.
Nomikos, George
Felder, Christian C.
Bernauer, Mark
Kinon, Bruce J.
Baker, Robert W.
Hay, Donald
Roth, H. John
Dossenbach, Martin
Kaiser, Christopher
Beasley, Charles M.
Holcombe, John H.
Effron, Mark B.
Breier, Alan
Titel
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data
Ist Teil von
International journal of geriatric psychiatry, 2001-12, Vol.16 (S1), p.S33-S61
Ort / Verlag
Chichester, UK: John Wiley & Sons, Ltd
Erscheinungsjahr
2001
Quelle
Wiley Online Library - AutoHoldings Journals
Beschreibungen/Notizen
Objective Olanzapine (OLZ) is unique among currently available antipsychotic medications in its antagonism of a range of receptor systems including dopamine, norepinephrine, serotonin, acetylcholine, and histamine. Olanzapine's mechanistic complexity provides a broad efficacy profile in patients with schizophrenia and acute, pure or mixed mania. Patients experience symptomatic relief of mania, anxiety, hallucinations, delusions, and agitation/aggression and reduced depressive, negative, and some cognitive symptoms. This paper will review the safety profile of OLZ, focusing on the elderly, where data are available. Method Preclinical and clinical studies of OLZ are reviewed, with emphasis on its possible effects on the cholinergic system and the histamine H1 receptor. Weight change and related metabolic considerations, cardiac and cardiovascular safety, and motor function during treatment with OLZ are also reviewed. Results and Conclusion In vitro receptor characterization methods, when done using physiologically relevant conditions allow accurate prediction of the relatively low rate of anticholinergic‐like adverse events, extrapyramidal symptoms, and cardiovascular adverse events during treatment with OLZ. Currently available clinical data suggest olanzapine is predictably safe in treating adult patients of any age with schizophrenia and acute bipolar mania, as well as in treatment of patients with some types of neurodegenerative disorders. Copyright © 2001 John Wiley & Sons, Ltd.
Sprache
Englisch
Identifikatoren
ISSN: 0885-6230
eISSN: 1099-1166
DOI: 10.1002/1099-1166(200112)16:1+<::AID-GPS571>3.0.CO;2-5
Titel-ID: cdi_proquest_miscellaneous_21113108
Format
–
Schlagworte
Adverse Drug Reaction Reporting Systems
,
Aged
,
Alzheimer Disease - drug therapy
,
Alzheimer's dementia
,
Animals
,
Benzodiazepines
,
bipolar disorder
,
Brain - drug effects
,
dementia
,
diabetes
,
Drug Evaluation, Preclinical
,
geriatric
,
Humans
,
Neurologic Examination - drug effects
,
olanzapine
,
Pirenzepine - adverse effects
,
Pirenzepine - analogs & derivatives
,
Pirenzepine - therapeutic use
,
receptors
,
Receptors, Neurotransmitter - drug effects
,
safety
,
schizophrenia
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX